|
Index of reports
> Cases resulting in a serious event (23)
> Cases with Dyspnoea (6)
Below is the selection of adverse event reports related to MS Contin (Morphine) that includes cases resulting in a serious event where reactions include dyspnoea.
Adverse event in 42 year old female receiving MS Contin (Morphine)
Reported by a physician from United States on 2007-06-27
Patient: 42 year old female
Adverse reactions / side effects: Confusional State, Dyspnoea, Neuropathy Peripheral, Abnormal Behaviour, Drug Interaction, Mood Swings, Disease Progression
Suspect drug(s):
MS Contin
Dosage: 15 mg qd po
Administration route: Oral
Indication: Complex Regional Pain Syndrome
Start date: 2006-10-01
Namenda
Dosage: 10 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-12-13
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-12-14
End date: 2006-12-20
Namenda
Dosage: 5 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-11-01
End date: 2006-01-01
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Namenda
Dosage: 15 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Other drugs received by patient: Warfarin Sodium; Crestor; Darvocet; Spiriva; Levoxyl; Oxygen
Adverse event in female receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification on 2007-05-23
Patient: female
Adverse reactions / side effects: Lymphadenopathy, Pruritus, Urticaria, Scleroderma, Pharyngeal Oedema, Connective Tissue Disorder, Abscess Limb, Cutaneous Lupus Erythematosus, Ligament Injury, Pelvic Mass, Pain in Extremity, Osteomyelitis Chronic, Osteitis, Vertebral Injury, Throat Irritation, Dehydration, Lymphoma, Pharmaceutical Product Complaint, Therapeutic Agent Toxicity, Pain, Impaired Work Ability, Constipation, Nasal Oedema, Road Traffic Accident, Adrenal Insufficiency, Myocardial Infarction, Medication Residue, Dyspnoea, Joint Dislocation, Uterine Cancer, Lung Disorder, Alopecia, Memory Impairment, Syncope Vasovagal, Immune System Disorder
Adverse event resulted in: hospitalization, disablity
Suspect drug(s):
MS Contin
Dosage: 60 mg, unk
Indication: Systemic Lupus Erythematosus
MS Contin
Dosage: 100 mg, bid prn
Adverse event in female receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification on 2007-05-18
Patient: female
Adverse reactions / side effects: Pruritus, Lymphadenopathy, Urticaria, Scleroderma, Pharyngeal Oedema, Connective Tissue Disorder, Abscess Limb, Cutaneous Lupus Erythematosus, Pelvic Mass, Ligament Injury, Pain in Extremity, Osteomyelitis Chronic, Osteitis, Vertebral Injury, Throat Irritation, Dehydration, Pharmaceutical Product Complaint, Lymphoma, Pain, Impaired Work Ability, Therapeutic Agent Toxicity, Constipation, Nasal Oedema, Road Traffic Accident, Adrenal Insufficiency, Myocardial Infarction, Medication Residue, Dyspnoea, Joint Dislocation, Uterine Cancer, Lung Disorder, Alopecia, Memory Impairment, Immune System Disorder, Syncope Vasovagal
Adverse event resulted in: hospitalization, disablity
Suspect drug(s):
MS Contin (Morphine)
Adverse event in 42 year old female receiving MS Contin (Morphine)
Reported by a physician from United States on 2007-05-09
Patient: 42 year old female
Adverse reactions / side effects: Back Pain, Confusional State, Dyspnoea, Abnormal Behaviour, Condition Aggravated, Drug Interaction, Cognitive Disorder, Amnesia, Complex Regional Pain Syndrome, Neuropathy Peripheral, Mood Swings
Suspect drug(s):
MS Contin
Dosage: 15 mg qd po
Administration route: Oral
Indication: Complex Regional Pain Syndrome
Start date: 2006-10-01
Namenda
Dosage: 10 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-12-13
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-12-14
End date: 2006-12-20
Namenda
Dosage: 5 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-11-01
End date: 2006-01-01
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Namenda
Dosage: 15 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Other drugs received by patient: Warfarin Sodium; Crestor; Darvocet; Spiriva; Levoxyl; Oxygen
Adverse event in 42 year old female receiving MS Contin (Morphine)
Reported by a physician from United States on 2007-03-13
Patient: 42 year old female
Adverse reactions / side effects: Back Pain, Confusional State, Dyspnoea, Abnormal Behaviour, Drug Interaction, Amnesia, Disease Progression, Hyperaesthesia, Neuropathy Peripheral, Mood Swings
Suspect drug(s):
MS Contin
Dosage: 15 mg qd po
Administration route: Oral
Indication: Complex Regional Pain Syndrome
Start date: 2006-10-01
Namenda
Dosage: 10 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-12-13
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-12-14
End date: 2006-12-20
Namenda
Dosage: 5 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-11-01
End date: 2006-01-01
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Namenda
Dosage: 15 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Other drugs received by patient: Warfarin Sodium; Crestor; Darvocet (Propoxyphene / Acetaminophen); Spiriva; Levoxyl; Oxygen
Adverse event in 72 year old male receiving MS Contin (Morphine)
Reported by a consumer/non-health professional from United States on 2007-03-01
Patient: 72 year old male, weighing 83.0 kg (182.6 pounds)
Adverse reactions / side effects: Dyspnoea, Dizziness, Pulmonary Embolism
Adverse event resulted in: hospitalization
Suspect drug(s):
MS Contin
Dosage: 15 mg, bid
Indication: Drug USE FOR Unknown Indication
Start date: 2006-10-31
Msir Capsules
Dosage: 15 mg, q4h prn
Indication: Drug USE FOR Unknown Indication
Start date: 2006-10-31
SU - 011, 248 (Sunitinib Malate)
Dosage: 50 mg, daily
Administration route: Oral
Indication: Prostate Cancer
Start date: 2006-10-31
End date: 2006-11-25
Tamsulosin HCL
Dosage: .4 mg, daily
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Start date: 2006-10-31
End date: 2006-11-25
Other drugs received by patient: Zoladex; Atenolol; Digoxin; Warfarin Sodium; Lisinopril
|
